Search

everythinglearnresearchcommunity

for

Search:↓

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Tofacitinib taken by mouth helps treat hair loss in children.

The new drug delivery system effectively targets lung cancer cells.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

QLT0267 stops hair follicle cell growth and movement.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.